Fundz

Zyus Life Sciences reported raising $72,800 in an initial SEC Form D filing, from an offering of $726,000

PRIVATEAug 13, 2025$72.8K of $726.2K raised

Amount Raised

$72,800

$72,800 sold, per SEC Form D (first sale Jul 29, 2025)

Round Type

Seed

SaskatoonManufacturingHealthcare

Quick answer

Zyus raised $72,800 in a Seed round, dated July 29, 2025. Zyus is based in Saskatoon, Saskatchewan, Canada.

How much did Zyus raise?
Zyus raised $72,800 in a Seed round on July 29, 2025.
What does Zyus do?
Zyus is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management.
Where is Zyus based and how big is it?
Zyus is based in Saskatoon, Saskatchewan, Canada. Fundz records about 54 employees.
Who are the decision-makers at Zyus?
Fundz holds 3 contacts at Zyus. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Manufacturing around the same time

Companies in the same sectors as Zyus that raised within 45 days of this round, from Fundz verified event records.

  • Talphera, Inc. raised $17M on September 10, 2025.
  • Lucid Group raised $300M (Funding Round) on September 4, 2025.
  • RIVANNA raised $800K (Grant) on August 15, 2025.
  • InspireMD raised $40M on July 30, 2025.
  • Hadrian raised $260M (Series C) on July 17, 2025.
  • Momentis Surgical raised $14M on July 15, 2025.

Who to call at Zyus, and when

A new round usually means Zyus is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Zyus raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Zyus, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Zyus. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Zyus

Location

407 DOWNEY RD

Saskatoon, Saskatchewan, Canada

About

Zyus is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS’ unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients’ lives.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Zyus raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contacts27 people are listed at Zyus. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Zyus's next move

See what Strategic adds

Zyus raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.